Skip to main content

Table 4 Pathological findings

From: Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study

Variables

Total (n = 201)

TP (n = 50)

TC (n = 151)

p

Perineural invasion, n (%)

   

0.837

Negative

169 (84.1)

43 (86)

126 (83.4)

 

Positive

32 (15.9)

7 (14)

25 (16.6)

 

Lymphovascular invasion, n (%)

   

0.787

Negative

181 (90.0)

46 (92)

135 (89.4)

 

Positive

20 (10.0)

4 (8)

16 (10.6)

 

Resection margins, n (%)

   

1

R0

195 (96.5)

49 (98)

146 (96)

 

R1

5 ( 2.5)

1 (2)

4 (2.6)

 

R2

2 (1)

0 (0)

2 (1.4)

 

pCR, n (%)

   

0.469

Yes

66 (32.8)

19 (38)

47 (31.1)

 

No

135 (67.2)

31 (62)

104 (68.9)

 

Postop.T, n (%)

   

0.82

T0

82 (40.8)

21 (42)

61 (40.4)

 

T1-2

64 (31.8)

17 (34)

47 (31.1)

 

T3-4

55 (27.4)

12 (24)

43 (28.5)

 

Postop.N, n (%)

   

0.097

N0

140 (69.7)

40 (80)

100 (66.2)

 

N + 

61 (30.3)

10 (20)

51 (33.8)

 
  1. pCR: Pathologic complete remission